Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines

Methods : a Companion to Methods in Enzymology
E M Jaffee, D M Pardoll

Abstract

In preclinical models, tumor cells genetically altered to secrete cytokines or express costimulatory molecules can generate systemic antitumor immunity. In some studies, these tumor vaccines have been shown to eradicate micrometastases. These results have led to the initiation of numerous phase I clinical trials employing either genetically modified or allogenic tumor vaccines. This article addresses a number of issues related to the clinical development of cytokine gene-transduced tumor cell vaccines including: (1) the production of cytokine-secreting tumor vaccines; and (2) the preclinical feasibility and toxicity studies required for testing these vaccines in patients with cancer.

References

Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·B QuantinJ L Mandel
May 1, 1992·The Journal of Experimental Medicine·K InabaG Schuler
Dec 1, 1991·The Journal of Experimental Medicine·H HockT Blankenstein
Jan 21, 1992·International Journal of Cancer. Journal International Du Cancer·P G CoulieT Boon
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A LiptonA A Bartolucci
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P L FelgnerM Danielsen
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J M WilsonR C Mulligan
May 1, 1987·Journal of Virology·D ArmentanoE Gilboa
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·O Danos, R C Mulligan
Aug 1, 1986·Molecular and Cellular Biology·A D Miller, C Buttimore
Jul 1, 1967·The Journal of Experimental Medicine·J Lindenmann, P A Klein
Apr 1, 1973·Virology·F L Graham, A J van der Eb
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·H PotterP Leder
Jun 2, 1994·Nature·D M Pardoll
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H C HooverM G Hanna
Jul 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·E M JaffeeD M Pardoll

❮ Previous
Next ❯

Citations

Nov 20, 2008·Immunologic Research·Laurence M WoodYvonne Paterson
Aug 7, 2009·Human Gene Therapy·Evelien L J M SmitsViggo F I Van Tendeloo
Nov 20, 2002·The Journal of Gene Medicine·Franz SchererChristian Plank
Jun 10, 2011·Neurosurgical Review·Kenichiro IwamiToshihiko Wakabayashi
Apr 9, 2008·Journal of Biomedical Science·Annie A WuSara I Pai
Jun 3, 2010·Expert Opinion on Biological Therapy·Shanthi SivendranYvonne Saenger
Jun 25, 2002·Expert Opinion on Biological Therapy·Bela Bodey
Nov 1, 2001·Surgical Oncology Clinics of North America·P Burdiles, R L Rossi
Mar 24, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D M Pardoll
May 8, 2000·International Journal of Cancer. Journal International Du Cancer·E Y ChangT Wu
Jun 26, 2003·Neurosurgery·Robert M Prins, Linda M Liau
May 29, 2009·Journal of Experimental & Clinical Cancer Research : CR·Aldo Venuti
Aug 6, 1998·Journal of Biomedical Science·C H Chen, T C Wu
Dec 19, 2002·Surgical Oncology Clinics of North America·Jennifer F Tseng, Richard C Mulligan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.